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phosphate conjugated to tetanus toxoid). No trials assessed clinical or carriage outcomes. Twenty tri-
als examined immunological outcomes and found few relevant differences. Comparing polyribosylribitol
phosphate conjugated to tetanus toxoid 3p+0 with 2p+0, there was no difference in seropositivity at
the 1.0 ฀g/mL threshold by 6 months after the last primary dose (combined risk difference -0.02; 95%
confidence interval: -0.10, 0.06). Only small differences were seen between schedules starting at different
ages, with different intervals between primary doses, or with different intervals between primary and
booster doses. Individuals receiving a booster were more likely to be seropositive than those at the same
age who did not. CONCLUSIONS There is no clear evidence from trials that any 2p+1, 3p+0 or 3p+1
schedule of Hib conjugate vaccine is likely to provide better protection against Hib disease than other
schedules. Until more data become available, scheduling is likely to be determined by epidemiological
and programmatic considerations in individual settings.
DOI: https://doi.org/10.1097/INF.0b013e31829f0a7e





Low, Nicola; Redmond, Shelagh M; Rutjes, Anne W S; Martínez-González, Nahara A; Egger, Matthias;
di Nisio, Marcello; Scott, Pippa (2013). Comparing Haemophilus influenzae type b conjugate vaccine












































The Pediatric Infectious Disease Journal  •  Volume 32, Number 11, November 2013 www.pidj.com | 1245
VACCINE REPORTS
Background: The optimal schedule and the need for a booster dose are 
unclear for Haemophilus influenzae type b (Hib) conjugate vaccines. We 
systematically reviewed relative effects of Hib vaccine schedules.
Methods: We searched 21 databases to May 2010 or June 2012 and selected 
randomized controlled trials or quasi-randomized controlled trials that 
compared different Hib schedules (3 primary doses with no booster dose 
[3p+0], 3p+1 and 2p+1) or different intervals in primary schedules and 
between primary and booster schedules. Outcomes were clinical efficacy, 
nasopharyngeal carriage and immunological response. Results were com-
bined in random-effects meta-analysis.
Results: Twenty trials from 15 countries were included; 16 used vaccines 
conjugated to tetanus toxoid (polyribosylribitol phosphate conjugated to 
tetanus toxoid). No trials assessed clinical or carriage outcomes. Twenty 
trials examined immunological outcomes and found few relevant differ-
ences. Comparing polyribosylribitol phosphate conjugated to tetanus toxoid 
3p+0 with 2p+0, there was no difference in seropositivity at the 1.0 μg/mL 
threshold by 6 months after the last primary dose (combined risk difference 
−0.02; 95% confidence interval: −0.10, 0.06). Only small differences were 
seen between schedules starting at different ages, with different intervals 
between primary doses, or with different intervals between primary and 
booster doses. Individuals receiving a booster were more likely to be sero-
positive than those at the same age who did not.
Conclusions: There is no clear evidence from trials that any 2p+1, 3p+0 
or 3p+1 schedule of Hib conjugate vaccine is likely to provide better pro-
tection against Hib disease than other schedules. Until more data become 
available, scheduling is likely to be determined by epidemiological and pro-
grammatic considerations in individual settings.
Key Words: Haemophilus influenzae type b conjugate vaccine, vaccine 
schedules, systematic review, meta-analysis
(Pediatr Infect Dis J 2013;32:1245–1256)
Haemophilus influenzae type b (Hib) conjugate vaccines have led to large reductions in the incidence of invasive Hib dis-
ease, including meningitis and pneumonia, in countries that include 
them in their routine immunization schedule.1 Nevertheless, there 
are still more than 8 million cases of severe Hib disease worldwide 
annually in children under 5 years.2 Conjugate vaccines in use in 
2012 contained Hib capsular polysaccharide (polyribosylribitol 
phosphate [PRP]) conjugated to the nontoxic CRM197 variant of 
diphtheria toxin (PRP-HbOC), meningococcal outer membrane 
protein (PRP-OMP), or most commonly tetanus toxoid (PRP-T).1
Countries are faced with decisions about optimal schedules 
for vaccines recommended for infants. The 2006 World Health 
Organization position paper on Hib conjugate vaccines states that 
a 3-dose schedule can be used with 1 to 2 months between doses, 
starting as young as 6 weeks.3 The position paper does not explicitly 
recommend a booster dose but states that if given it should be at 12–
18 months of age. In 2012, most countries using Hib vaccine used 
a 3-dose primary schedule with no booster dose (3p+0 schedule). 
Some countries, mainly in Europe and the Americas, added a booster 
dose to the 3-dose primary schedule (3p+1 schedule) whereas other 
countries, mainly in Europe, used schedules with 2 primary doses and 
a booster (2p+1 schedule).4 Variation in Hib vaccination schedules 
reflects not only differences in the historical scheduling of childhood 
vaccines, setting-specific epidemiology, existing health service infra-
structure and coadministered vaccines but also uncertainties about 
the optimal number of primary doses, the interval between doses in 
the primary schedule and the need for a booster dose.5 Whilst the 
clinical efficacy of Hib conjugate vaccines has been summarized,6–9 
there have been no systematic reviews summarizing immunological, 
carriage and clinical outcomes from trials making head-to-head com-
parisons of different Hib vaccine schedules.
Here we systematically review the evidence from rand-
omized controlled trials (RCTs) or quasi-randomized trials about 
the relative effects of 2p+0, 3p+0, 2p+1 and 3p+1 schedules and the 
effects of different timing of Hib conjugate vaccine doses.
METHODS
The review process followed a protocol, which was com-
pleted before starting the review (Supplemental Digital Content 1, 
http://links.lww.com/INF/B612). Minor amendments were made 
after the review started, and these are recorded in the protocol docu-
ment. We report here results for the head-to-head comparisons of 
Hib conjugate vaccine schedules described in the protocol. Com-
parisons of Hib schedules to no Hib vaccination will be reported 
elsewhere.
Study Identification
The literature search covered 21 electronic databases 
from the earliest citation until May 2010. There were 5 data-
bases of published articles (AIM, Cochrane Library, LILACs, 
IndMED, Medline), 3 trial registries, 11 vaccine manufacturer 
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databases and 2 regulatory authority websites. Search strate-
gies included terms for “Hib” and “conjugate vaccine” adapted 
for each search engine (Supplemental Digital Content 2, http://
links.lww.com/INF/B613). In June 2012, the Medline search 
was updated, using a filter to identify RCTs (2012 search only), 
and the AIM, CENTRAL, LILACs and IndMED searches were 
updated using the 2010 search strategy. Eligible trial registra-
tions found in the 2010 search were also checked for new publi-
cations in June 2012.
Study Selection
Studies were considered eligible if they were randomized 
or quasi-randomized (eg, allocated according to date of birth) 
and examined children vaccinated with PRP-T, PRP-OMP or 
PRP-HbOC at less than 6 years of age. Trials were eligible if 
they assigned participants to the following comparisons: 3p+0 
vs. 2p+0; 3p+0 vs. 2p+1; 3p+1 vs. 2p+1; 3p+1 vs. 3p+0. We 
also included studies that compared different intervals between 
doses and different ages at the start of the primary schedule. We 
excluded studies where both the schedule and the PRP-conjugated 
molecule differed between available comparison groups so that 
no comparisons within the trial assessed the effect of schedule 
differences alone.
Outcomes included invasive Hib disease as a combined out-
come or separate diagnoses of Hib meningitis, pneumonia due to 
any cause, Hib pneumonia, epiglottitis, nasopharyngeal carriage 
of Hib, seropositivity after vaccination or geometric mean con-
centration (GMC) of PRP antibody. Seropositivity was defined by 
IgG antibody levels measured by enzyme-linked immunoassay or 
Farr-type radio-assay at threshold values of 0.15 and 1.0 μg/mL.10 
Only systematically collected clinical outcomes were considered 
eligible.
Each title and abstract was screened for eligibility by 2 
independent reviewers. The full texts of abstracts assessed by 1 
or both reviewers to be potentially eligible were then screened for 
eligibility by 2 reviewers. Data were extracted on to a structured 
piloted form (available on request). Data were extracted by 2 inde-
pendent reviewers, and differences were resolved by consensus. 
Items extracted included trial characteristics, outcomes, potential 
sources of heterogeneity and the risk of bias in individual trials.11 
The risk of bias was assessed by examining trial features including 
the adequacy of random sequence generation, adequacy of alloca-
tion concealment, the use of outcome assessor blinding and the 
type of analysis.12,13 Analysis types included modified intention-
to-treat (mITT) and per-protocol (PP). Modified intention-to-
treat is used to describe analyses that included all randomized (or 
assigned) participants who had outcome data available with the 
possible exclusion of those who received no doses of vaccine, and 
PP is used to describe those that additionally excluded individuals 
with other protocol violations. We did not contact authors to obtain 
additional information.
Analysis
We combined data statistically, where appropriate, using 
DerSimonian and Laird random-effects meta-analysis14 in STATA 
version 12 (StataCorp LP, College Station, TX). Between-trial het-
erogeneity was described using the I2 statistic, where values below 
25% represent low heterogeneity, up to 50% moderate heterogene-
ity, up to 75% severe heterogeneity and more than 75% very severe 
heterogeneity.15 Where multiple intervention groups (or “trial arms”) 
were available within a trial to make a comparison of 2 schedules, 
we compared the groups that were most similar except for the differ-
ence in schedule. The decision about intervention groups to compare 
was made by 2 senior reviewers (N.L. and P.S.) without reference 
to trial results. For immunological outcomes, and for both the 1.0 
and 0.15 ug/mL thresholds, we calculated the difference between 
groups in proportions seropositive (and 95% confidence intervals 
[CIs] using the normal approximation to the sampling distribution 
of the difference) and reported the risk difference as a proportion. 
A risk difference of 0.08 would indicate that an additional 8% of 
individuals in the first comparison group were seropositive than in 
the second comparison group (eg, 88% vs. 80%). Immunogenicity 
data were stratified according to the conjugated molecule (PRP-
HbOC, -OMP or -T). We report 1.0 μg/mL threshold data in figures 
in preference to 0.15 μg/mL threshold data because risk differences 
were generally larger at the higher threshold. We report GMC data 
where seropositivity data were not available. We did not assess the 
presence of small trials biases using funnel plots or the Egger test 
because few trials were available for most analyses.
RESULTS
The literature searches yielded a total of 4337 unique items; 
4032 items from the 2010 database and 305 from reference lists 
or repeat database searches. Of these, 4299 items were excluded 
(Fig. 1). The remaining 38 items referred to 20 randomized or 
quasi-randomized trials reporting on eligible comparisons and 
outcomes. Included studies are described in Table 1 and Supple-
mental Digital Content 3, http://links.lww.com/INF/B614.16–34 The 
20 trials were conducted in 15 countries in Africa, Asia, Europe 
and North and South America. Sixteen trials used PRP-T, 3 used 
PRP-OMP and 2 used PRP-HbOC. One trial used PRP-T in 2 trial 
groups and PRP-HbOC in 2 other groups (Chile 1). Five trials did 
not report the number of individuals assigned to each intervention 
group. Where numbers were reported, a total of 6312 infants were 
assigned to intervention groups analyzed in this review: 661 infants 
to 2p+0 schedules, 1194 to 3p+0, 300 to 2p+1 and 4157 to 3p+1 
schedules. The median number of participants in trials was 283 
(range 54–1782).
Risk of Bias in Methods of Included Studies
Table 2 shows methodological features that could influence 
the risk of bias for the 20 trials. All trials individually assigned 
participants to intervention groups, and only 1 trial was judged 
to be quasi-randomized (USA 3). Allocation concealment was 
assessed as adequate in 2 trials and inadequate in 1 trial. In 17 
trials, allocation concealment was not well enough described to be 
assessed. Outcome assessors (laboratory staff) were described as 
blinded in 11 of the 20 trials. Four trials reported mITT analyses 
(3 of which also conducted PP analyses but only stated that results 
were similar to mITT results), 9 reported PP analyses (2 of which 
also conducted mITT analyses but only stated that results were 
similar to PP results) and for 7 trials it was not clear which analysis 
was reported.
Head-to-head Comparisons Between Schedules
There were no eligible clinical or carriage outcome data from 
trials that compared different schedules of Hib vaccination. Twenty 
trials examined eligible schedule comparisons and presented sero-
positivity or GMC data. Nine of these provided data for compari-
sons of schedules with different numbers of doses in the primary or 
booster schedules and 14 of these provided data for comparisons of 
schedules with the same number of doses but different timings. Fig-
ures in Supplemental Digital Content 4 and 5, http://links.lww.com/
INF/B615 and http://links.lww.com/INF/B616, show seropositivity 
(≥0.15 and ≥1.0 μg/mL) for all trial arms used in eligible compara-
tive analyses.
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Number of Doses in Primary and Booster Schedules, 
Immunological Data
3p+0 Versus 2p+0 Schedules. Seven trials provided data for 
this comparison (Chile 1, Chile 2, Guatemala, Netherlands, Niger, 
Sweden, USA 2). Six examined PRP-T and 2 examined PRP-
HbOC (1 trial examined both). Six trials reported seropositivity 
(Chile 1, Chile 2, Guatemala, Netherlands, Niger, Sweden), and all 
trials reported GMC data.
Figure 2 shows the risk difference (≥1.0 μg/mL) for sero-
positivity between groups receiving 3p+0 and 2p+0 schedules for 
trials where the interval between the last dose and blood draw was 
the same for both arms. In 3 trials, examining PRP-T (Chile 1, 
Niger, Sweden), neither the 2p nor the 3p schedule was consist-
ently favored and heterogeneity was high (I2 90% at the 1.0 μg/mL 
threshold and 67% at the 0.15 μg/mL threshold, shortly after the 
last primary dose). By 6 months after the last primary dose, there 
was no difference between the schedules at the 1.0 μg/mL threshold 
(combined risk difference −0.02; 95% CI: −0.10, 0.06) and no het-
erogeneity (I2 0%). Heterogeneity remained high 6 months after the 
last primary dose at the 0.15 μg/mL threshold (I2 75%).
One trial (Chile 1) examined PRP-HbOC and presented 
seropositivity data. Point estimates favored the 3p group, but 
the confidence interval included the null effect. The trial which 
reported only GMC (USA 2) examined PRP-HbOC and compared 
a birth dose plus doses at 2 and 4 months of age with doses at 2 and 
4 months of age. Two months after the last dose, the reported GMC 
in the 3p group (birth dose group) was 0.93 μg/mL (95% CI: 0.48, 
1.69) and 0.20 μg/mL (95% CI: 0.10, 0.29) in the 2p group.
3p Versus 2p+1 Schedules. One trial (Sweden) using PRP-T 
provided data for this comparison. At 13 months of age (7 months 
after the 3p group received their last primary dose and 1 month 
after the 2p+1 group received their booster), the risk difference was 
−0.79 (95% CI: −0.87, −0.71) at the 1.0 μg/mL threshold and −0.20 
(95% CI: −0.27, −0.13) at 0.15 μg/mL, favoring the 2p+1 schedule.
3p+1 Versus 2p+1 Schedules. Two trials using PRP-T pro-
vided data on seropositivity for this comparison (Netherlands, 
Sweden). Proportions seropositive 1 month after the booster vac-
cinations were high and similar in both groups. The combined risk 
difference was 0.01 (95% CI: −0.03, 0.05) at the 1.0 μg/mL thresh-
old and 0.01 (95% CI: −0.01, 0.02) at 0.15 μg/mL with moderate 
(I2 56%) and low (I2 24%) heterogeneity, respectively.
3p+1 Versus 3p Schedules. Two trials examined PRP-T for 
this comparison (Canada 2, Europe). One reported seropositivity 
data (Europe) and both reported GMC. At 13 months of age (1 
month after the 3p+1 group received their booster dose), the 3p+1 
schedule resulted in higher seropositivity than the 3p schedule at 
both the 1.0 µg/mL (risk difference 0.59, 95% CI: 0.52, 0.67) and 
0.15 µg/mL thresholds (risk difference 0.16, 95% CI: 0.11, 0.22). 
One trial reported only GMC (Canada 2). Multiple intervention 
groups in this trial were available for comparison and not all are 
presented here. At 16 months of age, the intervention group that 
received a 3p schedule with a booster dose at 15 months of age 
achieved a GMC of 29.92 μg/mL (95% CI: 24.58, 36.43, Canada 
2) and a group which had received a 3p schedule with no booster 
dose by 16 months of age achieved a GMC of 0.32 μg/mL (95% CI: 
0.25, 0.41, Canada 2).
Age at Start of Primary Schedule, Immunological Data
Eight trials compared schedules with the same number of 
doses, in which the first dose was given earlier or later (Belgium, 
Chile 2, China 1, China 2, Gambia 1, Gambia 2, Netherlands, Tur-
key). Seven examined PRP-T, and 1 examined PRP-OMP (Gambia 
1). Seven trials reported seropositivity data, and 8 reported GMC. 
Seropositivity results at the 1.0 µg/mL threshold are shown in 
Figure 3. Some schedule comparisons differed in both the age at 
first dose and in the interval between doses in the primary schedule. 
There were only small differences in seropositivity between sched-
ules and heterogeneity was low. The combined risk difference 1 
month after the last primary dose was 0.02 (95% CI: −0.01, 0.05) at 
the 1.0 μg/mL threshold, based on 3 trials (I2 1%). It was 0.01 (95% 
CI: 0.00, 0.02) at 0.15 μg/mL based on 4 trials (I2 0%).
The trial which reported only GMC (Gambia 2) compared 
PRP-T doses at 2 and 4 months to doses at 1 and 3 months of age. 
One month after the last dose of vaccine, the GMC was 0.41 μg/mL 
(95% CI: 0.28, 0.61) in infants receiving the first dose at 2 months 
and 0.26 μg/mL (95% CI: 0.19, 0.35) in the group with the earlier 
4032 items from initial database searches screened on title and abstract:
Medline 2692; Cochrane Library 516; AIM 7; IndMED 8; LILACs 151;  Manufacturer 
websites 202; WHO Portal 176; mRCT 204; FDA 42; EMEA 34 
3502 items excluded:
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start. One study comparing a birth dose of PRP-HbOC plus doses 
at 2, 4 and 6 months of age with doses at 2, 4 and 6 months (USA 
2) concluded that antibody levels were not higher after a birth dose.
Interval Between Doses, Immunological Data
Longer Versus Shorter Interval in Primary Schedules. Five 
trials provided immunological data comparing longer and shorter 
intervals in the primary schedule (Belgium, France, Turkey, USA 
1, USA 3). Four trials compared 2-month intervals with 1-month 
intervals (Belgium, France, Turkey, USA 3); 3 used 3p schedules 
to PRP-T and reported both seropositivity and GMC data (Bel-
gium, France, Turkey) and 1 used a 2p schedule with PRP-OMP 
and reported GMC data only (USA 3). At the 1.0 µg/mL threshold, 
neither the 2-month nor the 1-month interval schedule was consist-
ently favored, but results were heterogeneous (Fig. 4). At the 0.15 
µg/mL threshold, no difference was seen between the schedules 
and heterogeneity was low: the combined risk difference 1 month 
after the last primary dose was 0.00 (95% CI: −0.02, 0.02), I2 0%. 
The trial using PRP-OMP (USA 3) was quasi-randomized, using 
alternation for assignment of interventions. The mean age at first 
vaccination was older in the 2-month interval group than in the 
1-month interval group (4.1 and 3.2 months, respectively). Age-
adjusted GMCs 1 month after the second vaccination were 3.95 μg/
mL (95% CI: 2.63, 5.92) in the 2-month interval group and 2.32 
μg/mL (95% CI: 1.48, 3.64) in the 1-month interval group. One 
trial compared 4-month intervals to 2-month intervals using PRP-
OMP (USA 1), but results were difficult to interpret because the 
interval between vaccination and blood sampling differed between 
the groups being compared.
Longer Versus Shorter Interval Between Primary and 
Booster Schedules. Seven trials examined PRP-T and provided 
seropositivity and GMC data (Canada 1, Canada 2, Canada 3, Chile 
2, China 1, Europe, France). There were no differences in seroposi-
tivity 1 month after the booster dose and little between-study het-
erogeneity. The combined risk difference was 0.00 (95% CI: −0.01, 
0.01) at the 1.0 μg/mL threshold (Fig. 5) and 0.00 (95% CI: −0.01, 
0.01) at 0.15 μg/mL, with I2 14% and I2 0%, respectively.
DISCUSSION
Immunological data in this systematic review showed 
few differences that were both consistent and clinically relevant 
between Hib conjugate vaccine schedules with 2 or 3 primary 
doses or between schedules with different intervals between doses. 
Participants who had received booster doses were more likely to 
be seropositive than those of the same age who had not. There is 
an absence of clinical outcome or nasopharyngeal carriage data in 
head-to-head comparisons of Hib schedules.
This study is, to our knowledge, the first systematic review 
to examine the evidence from head-to-head comparisons of differ-
ent Hib conjugate vaccine schedules. The wide search means that 
relevant RCTs are unlikely to have been missed. We also attempted 
a detailed assessment of potential sources of heterogeneity and bias, 
but many trials were not reported completely enough for the risk 
TABLE 1. Summary of Included Studies
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of bias to be assessed. A limitation identified by this review was 
the paucity of data on several outcomes and comparisons of inter-
est. We did not include data from observational studies because 
well-conducted RCTs are at lower risk of bias than observational 
study designs,35,36 and because observational studies have been 
summarized elsewhere.37,38 The potential for bias does remain in 
many of the included trials, with allocation concealment, blinding of 
outcome assessors and exclusions after randomization being key trial 
design features influencing the risk of bias within trials.39 In particu-
lar, many trials in this review explicitly excluded some randomized 
TABLE 1. Continued
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All times are in months of age unless otherwise stated. One reference is supplied for each trial in this table. A complete list of references for each trial can be found in Supple-
mental Digital Content 3, http://links.lww.com/INF/B614.
*Multiple groups provide this comparison for this trial. Results presented compare a group receiving PRP-T and DTaP in separate syringes at 3, 4, 5 months with a group receiv-
ing PRP-T and DTaP in separate syringes at 2, 4, 6 months. Another group receiving PRP-T at 3, 4, 5 months in the same syringe as DTaP.
†Number receiving vaccine; number randomized not reported.
‡Ages not stated, but the following information is given for the booster doses: “The intended schedule of immunization was met for each child with single exceptions at 15 months 
(one week late) and 18 months (2 weeks late).”
§Multiple groups provide this comparison for this trial. Results presented compare a group receiving PRP-T at 3, 5, 7 months and DTaP combined with IPV at 2, 4, 6 months with 
a group receiving PRP-T at 2, 4, 6 months and DTaP combined with IPV at 2, 4, 6 months in another limb. Other groups receiving PRP-T at 3, 5, 7 months either received oral polio 
vaccine instead of IPV or had DTaP and IPV given as separate injections. The other group receiving PRP-T at 2, 4, 6 months received PRP-T in the same syringe as DTaP and IPV.
¶Number randomized to each group not reported. Seven hundred ten infants randomized to 5 groups (not all included here).
║Multiple groups provide this comparison for this trial. Results presented compare a group receiving PRP-T, IPV and DTaP in the same syringe at 3, 4, 5 months with a group 
receiving PRP-T, IPV and DTaP in the same syringe at 2, 3, 4 months. Another group receiving PRP-T at 3, 4, 5 months received DTaP and IPV separately at the same time (ie, 3 
separate syringes).
**Multiple groups provide this comparison for this trial. Results presented compare a group receiving PRP-T, IPV and DTaP in the same syringes at 3, 4, 5 months with a group 
receiving PRP-T, IPV and DTaP in the same syringes at 2, 3, 4 months. Another group receiving PRP-T at 2, 3, 4 months received DTaP in the same syringe and IPV at the same 
time but in a separate syringe.
††Type of conjugate vaccines for the primary series was not specified in this trial.
‡‡Multiple groups exist for the 3p + b12 schedule in this trial. Results presented compare a group receiving 3p then meningococcal conjugate vaccine at 12 months and PRP-T at 
13 months with a group receiving 3p then PRP-T at 12 months.
§§Ages not stated, but the following information is given: “Full compliance with the vaccination schedule and blood sampling was achieved by 85 infants in group A (immunized 
with two doses of vaccine at 1 and 3 months) and by 56 in group B (immunized at 2 and 4 months).”
¶¶Multiple groups provide this comparison for this trial. Results presented compare a group receiving PRP-T at 3, 4, 5 + b11 months and diphtheria, tetanus, whole-cell pertussis 
vaccine combined with IPV as a separate injection from PRP-T at 3, 4, 5 + b11 months with a group receiving PRP-T at 6, 7 + b13 months and diphtheria, tetanus, whole-cell pertus-
sis vaccine combined with IPV (not with PRP-T) at 3, 4, 5 + b11 months. The other group receiving PRP-T at 3, 4, 5 + b11 months received PRP-T in the same syringe as diphtheria, 
tetanus, whole-cell pertussis vaccine and IPV.
║║Ages not stated, but most doses were given on time: “805 injections were administered. Seven injections were given 1 to 6 days out of time range, 2 injections were given >1 
month out of time range.”
***Number analyzed; number of randomized or immunized children not reported.
†††The group receiving 2, 4, 6 PRP-HbOC received the 3rd dose at a mean age of 6.7 months. Other groups and doses not reported.
‡‡‡Total recruited, randomized and immunized; numbers per group not reported.
3p indicates 3-dose primary schedule where intended ages at vaccination not specified; +b, booster dose given at number of months indicated. DTaP, diphtheria, tetanus, acellular 
pertussis vaccine; Hib, Haemophilus influenzae type b vaccine; IPV, inactivated polio vaccine; Men A and C vaccines, conjugate or polysaccharide meningococcal A and C vaccines; 
NR, not reported; p, primary course; PRP, polyribosylribitol phosphate; PRP-HbOC, polyribosylribitol phosphate conjugated to diphtheria toxin CRM197; PRP-OMP, polyribosylribitol 
phosphate conjugated to outer membrane protein of Neisseria meningitidis; PRP-T, polyribosylribitol phosphate conjugated to tetanus toxoid; SD, standard deviation.
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All assessments based on information contained in published articles or prepublication articles. Authors of individual trials were not contacted for information on methodological 
features. One reference is supplied for each trial in this table. A complete list of references for each trial can be found in Supplemental Digital Content 3, http://links.lww.com/INF/
B614.
mITT indicates modified intention-to-treat analysis, similar to an intention-to-treat analysis but with some modifications to inclusion criteria such as excluding those who 
did not receive a first dose of vaccine; PP, per-protocol analysis, analysis where individuals with protocol violations (such as not receiving the intended vaccination schedule) are 
excluded.
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individuals by conducting only a PP analysis. For some design fea-
tures, it is difficult to categorize the risk of bias if the design feature 
is poorly described. For example, an incomplete description of allo-
cation concealment could be compatible with either a high or low 
risk of bias; if allocation was adequate, the risk of bias is low but if 
allocation concealment was not well conducted, bias might occur if 
it can be easily predicted which individuals are more or less likely 
to seroconvert. Incomplete descriptions for features such as blinding 
are less important when considering immunological results where 
outcomes are assessed by laboratory technicians. It is possible and 
even likely that outcome assessors were blinded, even if this was 
not reported. Even if the laboratory staff are not blinded, automated 
procedures are likely to reduce the risk of bias.
The immunological data from available trials do not clearly 
favor either a 2-dose or a 3-dose primary schedule. There were 
also no important differences in seropositivity for PRP-T sched-
ules starting at either 2 versus 3 months or PRP-OMP schedules 
starting at 1 versus 2 months of age. Available clinical data show 
good protection against invasive Hib disease with 2p+0 schedules 
using PRP-OMP,40 and with 3p+0 schedules using PRP-T or PRP-
HbOC,40–44 when compared with no Hib vaccine, and these data 
have been summarized several times.6–9 However, estimates of vac-
cine efficacy from different trials cannot be compared directly as 
evidence of equivalence or superiority of 1 particular schedule, and 
there are too few trials for a network meta-analysis, which would 
allow such a comparison.45,46
Two-month intervals between doses in the primary schedule 
were not shown to be consistently more immunogenic than 1-month 
intervals. Meta-analyses either showed marked heterogeneity 
or showed little heterogeneity and no difference between 2- and 
1-month intervals. It is challenging to draw conclusions about clini-
cal efficacy based on immunological findings because the clinical 
relevance of Hib seropositivity levels and GMCs are not well estab-
lished in general,10 and also because of differences in the schedules 
compared within each study other than the difference of interest. 
Data from an observational review found no strong evidence from 
cohort or case-control studies that the choice of intended intervals 
of 1 or 2 months between doses affects vaccine effectiveness,38 but 
differences between the intended and actual schedules and other 
factors such as herd immunity in the population again add com-
plexity to interpretation.5
A booster dose after a primary series of either 2 or 3 doses of 
Hib conjugate vaccine results in high levels of seropositivity. There 
was no evidence from trials that the age at which the booster dose 
is given or the interval between the primary series and the booster 
dose affects the level of seropositivity. Seropositivity levels in chil-
dren after a booster dose are much higher than in children who 
received the same primary schedule without a booster. The interval 
between the last vaccine dose and blood draw is, however, shorter in 
children receiving the booster than in those who received only the 
primary schedule, and it is not clear if differences in antibody levels 
can be interpreted as differences in protection from Hib disease.10 
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This review was not designed to collect data about antibody persis-
tence, and therefore, caution should be taken when examining such 
data from this review. However, when data from individual groups 
in trials eligible for this review are plotted alongside each other 
(Figs., Supplemental Digital Content 4 and 5, http://links.lww.com/
INF/B615 and http://links.lww.com/INF/B616), it can be seen that 
the proportion seropositive tends to be higher soon after a booster 
dose than soon after the last primary dose, or several months after 
the last primary dose, particularly at the 1.0 μg/mL threshold. Tri-
als that assessed seropositivity more than 1 month after the last 
primary dose showed generally lower proportions seropositive 
than those assessing seropositivity 1 month after the last primary 
dose. In the 1 trial with long follow up after a booster dose, a high 
proportion of individuals remained seropositive at the 0.15 μg/mL 
threshold years after the booster dose and a much lower proportion 
at the 1.0 μg/mL threshold. These trends are in general agreement 
with studies that have found sustained antibody persistence after a 
booster dose.47,48 The United Kingdom experienced an increase in 
Hib cases several years after an initial decline in cases subsequent 
to the introduction of a 3p+0 schedule (2, 3, 4 months) alongside 
an early catch-up  campaign. Cases again declined after 2 booster 
campaigns and the introduction of a routine booster dose to the 
vaccine schedule.49 However, the situations in which a booster dose 
should be used remain unclear and might relate to local epidemiol-
ogy, coadministered vaccines and the potential for natural boosting 
as well as other factors.50,51
This review did not aim to examine the effects of coadmin-
istrated vaccines on Hib conjugate vaccine efficacy, which is best 
examined in trials comparing groups with different coadministered 
vaccines but with the same schedule. However, conclusions from 
our review about the relative effects of different schedules do not 
change when restricted to trials that coadministered acellular per-
tussis vaccine or trials that coadministered whole-cell pertussis 
vaccine. In analyses that included both trials in which whole-cell 
pertussis vaccine was coadministered and trials in which acellular 
pertussis vaccine was coadministered, the relative effects of differ-
ent schedules of Hib vaccine did not appear to change substantially 
between studies. However, owing to the limited availability of data 
in each analysis, this could not be formally assessed using statistical 
methods such as meta-regression. The observational review con-
ducted simultaneously with our review found no strong evidence 
from cohort studies that coadministration with acellular pertussis 
vaccine–reduced vaccine effectiveness, but 2 case-control studies 
conducted in the United Kingdom provided some evidence of a 
reduction.38,51,52 Further carefully conducted systematic reviews of 
RCTs, as well as observational data, could provide useful informa-
tion about this and other questions about Hib vaccine scheduling.
Hib conjugate vaccine 2p+1, 3p+0 and 3p+1 schedules are 
all likely to provide protection against Hib disease and, until further 
data about the relative effects of different Hib vaccine schedules are 
available, the choice of schedule is likely to depend on the setting. 
For example, in settings where the burden of severe Hib disease lies 
with children under 1 year of age, it might be more appropriate to 
provide 3 doses of Hib vaccine early in life. In settings where the 
disease burden occurs later, or where a resurgence of Hib cases 
is seen after the introduction of Hib vaccine, it might be advanta-
geous to use a schedule where the third dose is given as a booster. 
Programmatic considerations are also likely to influence the choice 
of Hib vaccine schedule. Costs of vaccine administration are likely 
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is combined with other routine scheduled health visits. Addition-
ally, most Hib vaccines are administered as combined vaccines, 
which means that the scheduling of the other coadministered vac-
cines must also taken into account when choosing a Hib vaccine 
schedule.
Future decisions relating to Hib vaccination could be 
informed by well-conducted RCTs with head-to-head comparisons 
of schedules that collect data on clinical outcomes. Trials compar-
ing schedules would need to be extremely large to provide suffi-
cient statistical power to show difference between schedules, but 
trials of this type have been conducted for other vaccines.53
Variation in the burden of disease, health infrastructure and 
scheduling of other vaccines creates complexity in determining 
optimal vaccination schedules. Thus, information on the benefits 
of different vaccine schedules is essential if informed decisions are 
to be made. In this comprehensive systematic review, we highlight 
the absence of clinical and carriage data from trials comparing Hib 
vaccine schedules and scarce immunological data from such com-
parisons. We show there is no clear evidence from vaccine trials 
that any 2p+1, 3p+0 or 3p+1 schedule of Hib conjugate vaccine is 
likely to provide better protection against Hib disease than other 
schedules. Until additional data about the relative effects of differ-
ent Hib vaccine schedules are available, the choice of Hib vaccina-
tion schedule is likely to be determined by the epidemiological and 
programmatic conditions in individual settings.
ACKNOWLEDGMENTS
We thank the WHO secretariat and participants at expert 
meetings at WHO for their input, discussion and comments on this 
review. We also thank the World Health Organization and the Swiss 
National Science Foundation (grant no. 138490) for funding this 
project.
REFERENCES
 1. Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate 
vaccine use and effectiveness. Lancet Infect Dis. 2008;8:435–443.
 2. Watt JP, Wolfson LJ, O’Brien KL, et al.; Hib and Pneumococcal Global 
Burden of Disease Study Team. Burden of disease caused by Haemophilus 
influenzae type b in children younger than 5 years: global estimates. Lancet. 
2009;374:903–911.
 3. World Health Organization. WHO position paper on Haemophilus influen-
zae type b conjugate vaccines. Wkly Epidemiol Rec. 2006;81:445–452.
 4. World Health Organization. WHO Vaccine Preventable Diseases Monitoring 
System: Immunization schedules by antigen. Available at: http://apps.who.
int/immunization_monitoring/globalsummary/schedules. Accessed July 29, 
2013.
 5. Fitzwater SP, Watt JP, Levine OS, et al. Haemophilus influenzae type b con-
jugate vaccines: considerations for vaccination schedules and implications 
for developing countries. Hum Vaccin. 2010;6:810–818.
 6. Swingler G, Fransman D, Hussey G. Conjugate vaccines for preventing 
Haemophilus influenzae type B infections. Cochrane Database Syst Rev. 
2007:CD001729.
 7. Obonyo CO, Lau J. Efficacy of Haemophilus influenzae type b vaccination of 
children: a meta-analysis. Eur J Clin Microbiol Infect Dis. 2006;25:90–97.
 8. Griffiths UK, Clark A, Gessner B, et al. Dose-specific efficacy of Haemophilus 
influenzae type b conjugate vaccines: a systematic review and meta-analysis 
of controlled clinical trials. Epidemiol Infect. 2012;140:1343–1355.
 9. Theodoratou E, Johnson S, Jhass A, et al. The effect of Haemophilus influen-
zae type b and pneumococcal conjugate vaccines on childhood pneumonia 
incidence, severe morbidity and mortality. Int J Epidemiol. 2010;39(suppl 
1):i172–i185.
 10. Goldblatt D, Assari T. Immunological basis for immunization series. 
Module 9: Haemophilus influenzae type b. 2007. Available at: http://whqlib-
doc.who.int/publications/2007/9789241596138_eng.pdf. Accessed January 
24, 2013.
 11. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing 
the quality of controlled clinical trials. BMJ. 2001;323:42–46.
 12. Nüesch E, Trelle S, Reichenbach S, et al. The effects of excluding patients 
from the analysis in randomised controlled trials: meta-epidemiological 
study. BMJ. 2009;339:b3244.
 13. Nüesch E, Reichenbach S, Trelle S, et al. The importance of allocation con-
cealment and patient blinding in osteoarthritis trials: a meta-epidemiologic 
study. Arthritis Rheum. 2009;61:1633–1641.
 14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin 
Trials. 1986;7:177–188.
 15. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. 
Stat Med. 2002;21:1539–1558.
 16. Hoppenbrouwers K, Kanra G, Roelants M, et al. Priming effect, immu-
nogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid 
conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) com-
bination vaccine administered to infants in Belgium and Turkey. Vaccine. 
1999;17:875–886.
 17. Scheifele DW, Guasparini R, Lavigne P. A comparative study of PENTA 
vaccine booster doses given at 12, 15, or 18 months of age. Vaccine. 
1999;17:543–550.
 18. Scheifele DW, Halperin SA, Rubin E, et al. Safety and immunogenicity of 
a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, 
polio, and haemophilus influenzae type B conjugate) when administered as 
a fourth dose at 15 to 18 months of age. Hum Vaccin. 2005;1:180–186.
 19. Scheifele DW, Halperin SA, Ochnio JJ, et al. Immunologic considerations 
for the timing of the booster dose of 7-valent pneumococcal conjugate vac-
cine in young children. Pediatr Infect Dis J. 2007;26:387–392.
 20. Lagos R, Valenzuela MT, Levine OS, et al. Economisation of vaccination 
against Haemophilus influenzae type b: a randomised trial of immunogenic-
ity of fractional-dose and two-dose regimens. Lancet. 1998;351:1472–1476.
 21. Lagos R, Kotloff K, Hoffenbach A, et al. Clinical acceptability and 
immunogenicity of a pentavalent parenteral combination vaccine contain-
ing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and 
Haemophilus influenzae type b conjugate antigens in two-, four- and six-
month-old Chilean infants. Pediatr Infect Dis J. 1998;17:294–304.
 22. Li RC, Li FX, Li YP, et al. Antibody persistence at 18–20 months of age and 
safety and immunogenicity of a booster dose of a combined DTaP-IPV//
PRP approximately T vaccine compared to separate vaccines (DTaP, PRP 
approximately T and IPV) following primary vaccination of healthy infants 
in the People’s Republic of China. Vaccine. 2011;29:9337–9344.
 23. GlaxoSmithKline. Immunogenicity and safety of GlaxoSmithKline 
Biologicals’ DTPa-IPV/Hib (Infanrix-IPV+Hib™) in infants. Results sum-
mary for study ID 112584. Available at: http://www.gsk-clinicalstudyregis-
ter.com. Accessed January 24, 2013.
 24. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investi-
gational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus 
toxoid conjugate vaccine co-administered with Infanrix™ hexa is immu-
nogenic, with an acceptable safety profile in 12-23-month-old children. 
Vaccine. 2011;29:4264–4273.




 26. Campbell H, Byass P, Ahonkhai VI, et al. Serologic responses to an 
Haemophilus influenzae type b polysaccharide-Neisseria meningitidis 
outer membrane protein conjugate vaccine in very young Gambian infants. 
Pediatrics. 1990;86:102–107.
 27. Mulholland EK, Byass P, Campbell H, et al. The immunogenicity and safety 
of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 
Gambian infants. Ann Trop Paediatr. 1994;14:183–188.
 28. Asturias EJ, Mayorga C, Caffaro C, et al. Differences in the immune response 
to hepatitis B and Haemophilus influenzae type b vaccines in Guatemalan 
infants by ethnic group and nutritional status. Vaccine. 2009;27:3650–3654.
 29. Labadie J, Sundermann L, Rumke H. The DPT-IPV Hib vaccine study group. 
Multi-center study on the simultaneous administration of DPT-IPV and Hib 
PRP-T vaccines. Rijksinstituut voor Volksgezondheid en Milieu RIVM. 
1996. Available at: http://www.rivm.nl/bibliotheek/rapporten/124001003.
html. Accessed January 24, 2013.
 30. Campagne G, Garba A, Schuchat A, et al. Response to conjugate 
Haemophilus influenzae B vaccine among infants in Niamey, Niger. Am J 
Trop Med Hyg. 1998;59:837–842.
 31. Carlsson RM, Claesson BA, Selstam U, et al. Safety and immunogenicity of 
a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-
Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 
months of age. Pediatr Infect Dis J. 1998;17:1026–1033.
Low et al The Pediatric Infectious Disease Journal • Volume 32, Number 11, November 2013
1256  |  www.pidj.com  © 2013 Lippincott Williams & Wilkins
 32. Anderson EL, Decker MD, Englund JA, et al. Interchangeability of con-
jugated Haemophilus influenzae type b vaccines in infants. JAMA. 
1995;273:849–853.
 33. Lieberman JM, Greenberg DP, Wong VK, et al. Effect of neonatal immu-
nization with diphtheria and tetanus toxoids on antibody responses 
to Haemophilus influenzae type b conjugate vaccines. J Pediatr. 1995;126: 
198–205.
 34. Lenoir AA, Granoff PD, Granoff DM. Immunogenicity of Haemophilus 
influenzae type b polysaccharide-Neisseria meningitidis outer mem-
brane protein conjugate vaccine in 2- to 6-month-old infants. Pediatrics. 
1987;80:283–287.
 35. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 
statement: updated guidelines for reporting parallel group randomised tri-
als. BMJ. 2010;340:c332.
 36. Sibbald B, Roland M. Understanding controlled trials. Why are randomised 
controlled trials important? BMJ. 1998;316:201.
 37. O’Loughlin RE, Edmond K, Mangtani P, et al. Methodology and measure-
ment of the effectiveness of Haemophilus influenzae type b vaccine: system-
atic review. Vaccine. 2010;28:6128–6136.
 38. Jackson C, Mann A, Mangtani P, et al. Effectiveness of Haemophilus influ-
enzae type b (Hib) vaccines administered according to different schedules: 
systematic review and meta-analysis of observational data. Pediatr Infect 
Dis J. 2013;32:1261–1269.
 39. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. 
Dimensions of methodological quality associated with estimates of treat-
ment effects in controlled trials. JAMA. 1995;273:408–412.
 40. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a 
conjugate vaccine consisting of Haemophilus influenzae type b polysaccha-
ride and Neisseria meningitidis outer-membrane protein complex. N Engl J 
Med. 1991;324:1767–1772.
 41. Lagos R, Horwitz I, Toro J, et al. Large scale, postlicensure, selective vac-
cination of Chilean infants with PRP-T conjugate vaccine: practicality and 
effectiveness in preventing invasive Haemophilus influenzae type b infec-
tions. Pediatr Infect Dis J. 1996;15:216–222.
 42. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of 
Haemophilus influenzae type-b tetanus protein conjugate vaccine [cor-
rected] for prevention of pneumonia and meningitis in Gambian infants. 
Lancet. 1997;349:1191–1197.
 43. Gessner BD, Sutanto A, Linehan M, et al. Incidences of vaccine-preventable 
Haemophilus influenzae type b pneumonia and meningitis in Indonesian 
children: hamlet-randomised vaccine-probe trial. Lancet. 2005;365:43–52.
 44. Black SB, Shinefield HR, Fireman B, et al. Efficacy in infancy of oligo-
saccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in 
a United States population of 61,080 children. The Northern California 
Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect 
Dis J. 1991;10:97–104.
 45. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-
analysis. Stat Med. 1996;15:2733–2749.
 46. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treat-
ment comparisons. Stat Med. 2004;23:3105–3124.
 47. Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence 
following administration of a combination meningococcal serogroup C and 
haemophilus influenzae type b conjugate vaccine in healthy infants in the 
United Kingdom primed with a monovalent meningococcal serogroup C 
vaccine. Clin Vaccine Immunol. 2010;17:154–159.
 48. Southern J, McVernon J, Gelb D, et al. Immunogenicity of a fourth dose of 
Haemophilus influenzae type b (Hib) conjugate vaccine and antibody per-
sistence in young children from the United Kingdom who were primed with 
acellular or whole-cell pertussis component-containing Hib combinations in 
infancy. Clin Vaccine Immunol. 2007;14:1328–1333.
 49. Ladhani S, Slack MP, Heys M, et al. Fall in Haemophilus influenzae sero-
type b (Hib) disease following implementation of a booster campaign. Arch 
Dis Child. 2008;93:665–669.
 50. Slack MP, Azzopardi HJ, Hargreaves RM, et al. Enhanced surveillance of 
invasive Haemophilus influenzae disease in England, 1990 to 1996: impact 
of conjugate vaccines. Pediatr Infect Dis J. 1998;17(suppl 9):S204–S207.
 51. McVernon J, Andrews N, Slack MP, et al. Risk of vaccine failure after 
Haemophilus influenzae type b (Hib) combination vaccines with acellular 
pertussis. Lancet. 2003;361:1521–1523.
 52. McVernon J, Andrews N, Slack M, et al. Host and environmental fac-
tors associated with Hib in England, 1998–2002. Arch Dis Child. 
2008;93:670–675.
 53. Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumo-
coccal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) 
against invasive pneumococcal disease: a cluster randomised trial. Lancet. 
2013;381:214–222.
